Nile, Medtronic partner on heart failure therapy

Medtronic is partnering with San Mateo, CA-based Nile Therapeutics to develop a new outpatient treatment for sufferers of acutely decompensated heart failure. Financial details of the deal have not been disclosed.

Nile will focus on Phase I and II clinical trials for its proprietary natriuretic peptide, cenderitide, using Medtronic's diabetes pump technology, knowledge and cash flow. The first trial should be completed by the first quarter of 2012. According to the release, the Phase I trial will study the effects of cenderitide on heart failure patients when it is administered for 24 hours via a continuous subcutaneous drip.

"This collaboration will be an important step on our path to developing cenderitide as a potential new therapy for patients with cardiovascular and renal disease following hospitalization for acute heart failure," said Nile CEO Joshua Kazam.

- read the Nile release on the Medtronic pact
- and the other release about the drug itself

Suggested Articles

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.